Neferine
CAS No. 2292-16-2
Neferine( (-)-Neferine )
Catalog No. M18271 CAS No. 2292-16-2
Neferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 125 | In Stock |
|
| 50MG | 210 | In Stock |
|
| 100MG | 311 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNeferine
-
NoteResearch use only, not for human use.
-
Brief DescriptionNeferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity.
-
DescriptionNeferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity. Neferine can be helpful to increase the efficacy of DOX and to achieve anticancer synergism by curbing the toxicity. Neferine inhibited high glucose-induced endothelial apoptosis via blocking ROS/Akt/NF-κB pathway, which provides the evidence for using Neferine to treat diabetic vasculopathy. Neferine induced apoptosis in a dose-dependent manner with the hypergeneration of reactive oxygen species, activation of MAPKs, lipid peroxidation, depletion of cellular antioxidant pool, loss of mitochondrial membrane potential, and intracellular calcium accumulation.
-
In VitroNeferine down regulates hypoxia induced NF-κB p65 nuclear translocation and COX-2 expressions. Neferine reduces high-glucose-induced collagen production and inhibits TGF-β1-Smad, ERK and p38 MAPK signaling activation in cardiac fibroblasts. Cardiac fibroblasts (CFs) are cultured in HG medium with varying concentrations of Neferine (1, 2, or 5 μM). CCK-8 assays are carried out at different time points (24, 48, and 72 h). Compared with normal glucose (NG) and osmotic control (OC) treatments, High glucose (30 mM) treatment significantly increases the proliferation of CFs in a time-dependent manner (P<0.05). High glucose (HG)-induced CF proliferation is markedly attenuated by Neferine treatment at either 2 or 5 μM compared with vehicle treatment. However, 1 μM Neferine does not inhibit HG-induced proliferation of CFs. Therefore, 2 and 5 μM Neferine are used in the remaining experiments.
-
In VivoNeferine treatment at both low-dose (60 mg/kg/day by gavage) and high-dose (120 mg/kg/day by gavage) reduces the increment of collagen I, III and TGF-β1 protein expression induced by hyperglycemia.
-
Synonyms(-)-Neferine
-
PathwayNeuroscience
-
TargetGluR
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number2292-16-2
-
Formula Weight624.77
-
Molecular FormulaC38H44N2O6
-
Purity>98% (HPLC)
-
SolubilityDMSO : 62 mg/mL 99.24 mM;
-
SMILESCN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)OC)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
OSI-420
OSI-420 (Desmethyl Erlotinib, CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for human EGFR and EGFR autophosphorylation in tumor cells.
-
GYKI 52466 dihydroch...
GYKI 52466 dihydrochloride (GYKI 52466 2HCl) is a highly potent, orally active and selective AMPA/Kainate receptor antagonist with good blood-brain permeability and anticonvulsant activity that can be used to study neurological diseases such as Parkinson's and epilepsy.
-
Chelidamic acid
Chelidamic acid is a heterocyclic organic acid with a pyran skeleton. Chelidamic acid is inhibitors of glutamate decarboxylase with a Ki of 33 μM.
Cart
sales@molnova.com